Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications

Head and Neck

Volumn 37, Issue 5, 2015, Pages 763-770

  Perri, Francesco ^a   Pacelli, Roberto ^b   Della Vittoria Scarpati, Giuseppina ^c   Cella, Laura ^c   Giuliano, Mario ^c,d   Caponigro, Francesco ^a   Pepe, Stefano ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SALERNO   (Italy)

Author keywords

Akt; chemoradiotherapy; epidermal growth factor receptor (EGFR); head and neck squamous cell carcinoma; intracellular pathway; P53; radioresistance

Indexed keywords

ADENOVIRUS VECTOR; AMPHIREGULIN; BEVACIZUMAB; CETUXIMAB; CONTUSUGENE LADENOVEC; CYCLIN D1; DACTOLISIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INITIATION FACTOR 4E; K RAS PROTEIN; LONTUCIREV; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; PROTEIN P53; PUMA PROTEIN; RAPAMYCIN; RAS PROTEIN; TEMSIROLIMUS; TIPIFARNIB; TRANSFORMING GROWTH FACTOR; UNINDEXED DRUG; UVOMORULIN; VORINOSTAT; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; EGFR PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADVANCED CANCER; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRAL GENE THERAPY; VIRUS REPLICATION; WILD TYPE; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DRUG EFFECTS; FEMALE; HEAD AND NECK NEOPLASMS; MALE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; RISK ASSESSMENT; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROGNOSIS; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84928215725     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23837     Document Type: Article

References (73)

1. Ang KK, Andratschke NH, Milas L,. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004; 58: 959-965.
2. NCCN guidelines 2013. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed January 4, 2014.
3. Pignon JP, le Maître A, Maillard E, Bourhis J,; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
4. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
5. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C,. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2011; 15: 63-74.
6. Kumar R, Hung MC,. Signaling intricacies take center stage in cancer cells. Cancer Res 2005; 65: 2511-2515.
7. Bussink J, van der Kogel AJ, Kaanders JH,. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9: 288-296.
8. Hama T, Yuza Y, Saito Y, et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009; 14: 900-908.
9. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J,. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004; 58: 561-566.
10. Zhu X, Zhang F, Zhang W, He J, Zhao Y, Chen X,. Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol 2013; 108: 387-397.
11. Sun W, Long G, Wang J, Mei Q, Liu D, Hu G., Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis. Head Neck 2013. [Epub ahead of print].
12. Hoogsteen IJ, Marres HA, van den Hoogen FJ, et al. Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance. Int J Radiat Oncol Biol Phys 2012; 84: 807-814.
13. Saki M, Toulany M, Rodemann HP,. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother Oncol 2013; 108: 473-478.
14. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-940.
15. Corvò R,. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007; 85: 156-170.
16. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23: 5560-5567.
17. Eriksen JG, Steiniche T, Overgaard J,; Danish Head and Neck Cancer Study Group (DAHANCA). The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 2005; 74: 93-100.
18. Pedicini P, Nappi A, Strigari L, et al. Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol 2012; 7: 143.
19. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
20. Saki M, Toulany M, Rodemann HP,. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother Oncol 2013; 108: 473-478.
21. Awada A, Zhang S, Gil T, et al. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies. Curr Med Res Opin 2007; 23: 991-1003.
22. Li S, Takasu T, Perlman DM, et al. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003; 278: 3015-3022.
23. Hong KO, Kim JH, Hong JS, et al. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J Exp Clin Cancer Res 2009; 28: 28.
24. Bruzzese F, Leone A, Rocco M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011; 226: 2378-2390.
25. Toulany M, Baumann M, Rodemann HP,. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 2007; 5: 863-872.
26. Dent P, Yacoub A, Contessa J, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003; 159: 283-300.
27. Qiu W, Schönleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 1441-1446.
28. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013; 3: 761-769.
29. Yoshida K, Sasaki R, Nishimura H, et al. Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer. Head Neck 2010; 32: 646-655.
30. Alshareeda AT, Negm OH, Albarakati N, et al. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast Cancer Res Treat 2013; 139: 301-310.
31. Groselj B, Kerr M, Kiltie AE,. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother Oncol 2013; 108: 429-433.
32. Kuo ML, Chuang SE, Lin MT, Yang SY,. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 2001; 20: 677-685.
33. Zhan M, Han ZC,. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 2004; 19: 915-923.
34. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996; 16: 1722-1733.
35. Vlahos CJ, Matter WF, Hui KY, Brown RF,. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
36. Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008; 68: 206-215.
37. Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett 2014; 343: 24-32.
38. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-4062.
39. Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006; 5: 766-770.
40. Bauman JE, Arias-Pulido H, Lee SJ, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol 2013; 49: 461-467.
41. Bhatt VR, Ganti AK,. Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck. Oral Oncol 2013; 49: e25.
42. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP,. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-873.
43. Vousden KH, Lu X,. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
44. Gasco M, Crook T,. The p53 network in head and neck cancer. Oral Oncol 2003; 39: 222-231.
45. Murphy M, Ahn J, Walker KK, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13: 2490-2501.
46. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-590.
47. Yu J, Zhang L,. PUMA, a potent killer with or without p53. Oncogene 2008; 27 Suppl 1: S71-S83.
48. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G,. Frequent p53 mutations in head and neck cancer. Cancer Res 1992; 52: 5997-6000.
49. Couture C, Raybaud-Diogène H, Têtu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002; 94: 713-722.
50. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18: 290-300.
51. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
52. Csuka O, Remenár E, Koronczay K, Doleschall Z, Németh G,. Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer. Pathol Oncol Res 1997; 3: 204-210.
53. Valente LJ, Gray DH, Michalak EM, et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013; 3: 1339-1345.
54. Yoo GH, Moon J, Leblanc M, et al. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2009; 135: 869-874.
55. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-2232.
56. Nemunaitis J, Nemunaitis J,. Head and neck cancer: response to p53-based therapeutics. Head Neck 2011; 33: 131-134.
57. Pearson S, Jia H, Kandachi K,. China approves first gene therapy. Nat Biotechnol 2004; 22: 3-4.
58. Tassone P, Old M, Teknos TN, Pan Q,. p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol 2013; 49: 733-737.
59. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.
60. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806.
61. Yuki K1, Takahashi A, Ota I, et al. Sensitization by glycerol for CDDP-therapy against human cultured cancer cells and tumors bearing mutated p53 gene. Apoptosis 2004; 9: 853-859.
62. Ota I, Okamoto N, Yane K, et al. Therapeutic strategies for head and neck cancer based on p53 status. Exp Ther Med 2012; 3: 585-591.
63. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288.
64. Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, Koch WM,. p53-reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 2011; 47: 8-15.
65. Xie X, Piao L, Bullock BN, et al. Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene 2014; 33: 1037-1046.
66. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans,. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Monogr Eval Carcinog Risks Hum 2007; 89: 1-592.
67. Park BJ, Chiosea SI, Grandis JR,. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark 2010; 9: 325-339.
68. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J,. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-1998.
69. Cattani P, Hohaus S, Bellacosa A, et al. Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma. Clin Cancer Res 1998; 4: 2585-2589.
70. Kostareli E, Holzinger D, Hess J,. New concepts for translational head and neck oncology: lessons from HPV-related oropharyngeal squamous cell carcinomas. Front Oncol 2012; 2: 36.
71. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636.
72. Kofler B, Laban S, Busch CJ, Lörincz B, Knecht R,. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol 2014; 271: 1861-1867.
73. Pajares B, Trigo JM, Toledo MD, et al. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer 2013; 13: 26.